Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
RARE/Financial Reporting
Income Statements
13 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | - - | 2.00 | 51.00 | 103.00 | 271.00 | 351.00 | 363.00 | 434.00 | |
|
EPS
|
-0.30 | -0.71 | -1.21 | -2.08 | -3.96 | -6.21 | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | |
| Diluted in mil. | -0.30 | -0.71 | -1.21 | -2.08 | -3.96 | -6.21 | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | |
|
Profit
|
- - | - - | - - | - - | - - | - - | 2.00 | 50.00 | 94.00 | 264.00 | 335.00 | 335.00 | 389.00 | |
| Gross Margin | - - | - - | - - | - - | - - | 100.00 | 99.96 | 97.77 | 91.31 | 97.74 | 95.44 | 92.21 | 89.59 | |
| Pre Tax | -6.00 | -16.00 | -35.00 | -59.00 | -145.00 | -245.00 | -318.00 | -197.00 | -399.00 | -185.00 | -452.00 | -701.00 | -608.00 | |
| Profit Margin | - - | - - | - - | - - | - - | -184,841.35 | -12,187.52 | -382.75 | -385.14 | -68.39 | -128.91 | -193.14 | -140.12 | |
| ETR | -3.62 | 2.14 | 8.57 | 1.14 | 1.59 | -0.01 | 5.09 | -0.26 | -0.82 | -0.65 | -0.23 | -0.81 | 0.30 | |
| Net | -6.00 | -16.00 | -35.00 | -59.00 | -145.00 | -245.00 | -302.00 | -197.00 | -402.00 | -186.00 | -454.00 | -707.00 | -606.00 | |
| Profit Margin | - - | - - | - - | - - | - - | -184,867.67 | -11,567.34 | -383.75 | -388.31 | -68.84 | -129.20 | -194.71 | -139.70 | |
| EBITDA | -6.00 | -16.00 | -34.00 | -56.00 | -146.00 | -248.00 | -328.00 | -541.00 | -411.00 | -322.00 | -381.00 | -639.00 | -516.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | -186,471.43 | -12,593.49 | -1,051.94 | -396.98 | -118.98 | -108.56 | -175.99 | -119.02 | |
| Operating Income | -6.00 | -15.00 | -32.00 | -56.00 | -147.00 | -248.00 | -328.00 | -371.00 | -424.00 | -330.00 | -381.00 | -648.00 | -569.00 | |
| Operating Margin | - - | - - | - - | - - | - - | -186,471.43 | -12,593.49 | -721.18 | -408.98 | -121.80 | -108.63 | -178.60 | -131.08 | |
| Interest Income | - - | - - | - - | - - | 2.00 | 3.00 | 4.00 | 9.00 | 13.00 | 7.00 | 1.00 | 11.00 | 26.00 | |
| Loss | -6.00 | -15.00 | -32.00 | -56.00 | -147.00 | -248.00 | -331.00 | -422.00 | -527.00 | -601.00 | -733.00 | -1,012.00 | -1,003.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | -1.00 | -9.00 | -6.00 | -16.00 | -28.00 | -45.00 | |
|
Operating Expenses
|
-6.00 | -15.00 | -32.00 | -56.00 | -147.00 | -248.00 | -331.00 | -421.00 | -518.00 | -595.00 | -717.00 | -983.00 | -958.00 | |
| R&D | -4.00 | -12.00 | -27.00 | -45.00 | -114.00 | -183.00 | -231.00 | -293.00 | -357.00 | -412.00 | -497.00 | -705.00 | -648.00 | |
| G&A | -1.00 | -3.00 | -4.00 | -10.00 | -33.00 | -64.00 | -99.00 | -127.00 | - - | - - | - - | - - | - - | |
| SG&A | -1.00 | -3.00 | -4.00 | -10.00 | -33.00 | -64.00 | -99.00 | -127.00 | -161.00 | -182.00 | -219.00 | -278.00 | -309.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | -1.00 | -3.00 | -5.00 | -19.00 | -8.00 | -12.00 | -13.00 | -18.00 | -26.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -33.00 | -29.00 | -43.00 | -66.00 | |
| Other Expenses | - - | - - | -3.00 | -3.00 | - - | -2.00 | -10.00 | -174.00 | -24.00 | -144.00 | -71.00 | -52.00 | -39.00 | |
|
WA Shares Outstanding
|
23.00 | 23.00 | 29.00 | 28.00 | 36.00 | 39.00 | 42.00 | 49.00 | 56.00 | 60.00 | 67.00 | 69.00 | 73.00 | |
| Diluted | 23.00 | 23.00 | 29.00 | 28.00 | 36.00 | 39.00 | 42.00 | 49.00 | 56.00 | 60.00 | 67.00 | 69.00 | 73.00 |